M-CSF 蛋白, Human (CHO)

M-CSF (CSF-1) protein is a homodimeric hematopoietic growth factor and proinflammatory cytokine, belonging to the colony stimulating factor. M-CSF can act specifically on the monocyte-macrophage lineage, drive monocyte proliferation and differentiation into macrophages/osteoclasts, and induce M1 macrophages to enhance ADCC anti-tumor activity and M2 macrophages to promote VEGF angiogenesis^[1][2][3][4]. M-CSF Protein, Human (CHO) is a recombinant human M-CSF protein expressed in CHO cells with tag-free.

1. M-CSF Protein 蛋白特点^[1][2][3]
M-CSF，即巨噬细胞集落刺激因子，CSF-1，是二硫键连接的同源二聚体，属于集落刺激因子 (CSF) 家族。M-CSF 是一种具有多种糖基化位点的造血生长因子和促炎细胞因子，与 GM-CSF、G-CSF 同属造血生长因子家族。M-CSF 影响组织巨噬细胞的存活和功能，并具有抗肿瘤活性^[1]。M-CSF 在多种细胞中表达，如成纤维细胞、内皮细胞、基质细胞、巨噬细胞、平滑肌细胞和成骨细胞，存在多种亚型。M-CSF 可为分泌糖蛋白、细胞表面蛋白和蛋白聚糖，与其受体 CSF1R 结合^[2]。M-CSF 可特异性作用于单核-巨噬细胞谱系，参与单核细胞/巨噬细胞谱系细胞的发育和增殖，并参与破骨细胞的诱导。而破骨细胞对于骨和软骨的破坏以及类风湿性关节炎患者的关节周围骨质疏松变化非常重要^[3]。

2. M-CSF Protein 功能特点^[1][4]
M-CSF 在上游受 LPS、IFN-γ 调控，下游调控 IL-12、TNF-α 等炎症因子。M-CSF 诱导巨噬细胞极化为 M1 型，通过上调 CD80、CD16 等表面分子，来增强抗体依赖的细胞毒性 (ADCC)，发挥抗肿瘤作用。M-CSF 或诱导巨噬细胞极化为 M2 型，促进 VEGF 分泌及血管生成。

3. M-CSF Protein 的应用^[1][4][5][6]
肿瘤学：临床试验显示，M-CSF 联合单抗可增强肿瘤靶向杀伤，但其促血管生成作用可能促进转移。
感染与免疫：提升巨噬细胞抗真菌 (如念珠菌)、抗结核活性，用于免疫缺陷患者感染治疗。
造血修复：化疗/移植后恢复单核细胞计数，缩短中性粒细胞缺乏期。
骨疾病：调控破骨细胞，用于骨质疏松、类风湿关节炎研究。

M-CSF Protein (人源；20 ng/mL；72 h) 增强人单核细胞/巨噬细胞的抗体依赖性细胞毒性 (ADCC)，在效应细胞:靶细胞=20:1 时显著提升结肠癌细胞 (LS-174) 裂解率，且不依赖 TNF-α 分泌^[1]。
M-CSF Protein (人源；100 ng/mL；3-10 d) 促进单核细胞向巨噬细胞分化，伴随细胞体积增大、空泡化，并增强吞噬活性；3 d 时 VEGF mRNA 转录达峰，5 d 时 VEGF 分泌量最高 (1,802 pg/mL)^[4]。
M-CSF Protein (人源；50 ng/mL；6 d) 诱导人单核细胞分化为 M0-M 巨噬细胞，表现为 CD14+、CD16+ 等巨噬细胞标记物上调，且保留对 LPS/IFNγ 的 M1 极化响应能力^[5]。

M-CSF Protein (人源；20,000 U/day；静脉注射；每日 1 次；连续 4 天，间隔 3 天，共2个疗程) 降低小鼠 B16 黑色素瘤模型中的肺转移灶数量，并延长动物存活时间^[1]。
M-CSF Protein (人源；10-175 μg/kg/day；皮下注射/持续静脉输注 (CIVI) 7-14 天；每日 1 次；间隔 14 天后继续 3 个疗程) 在低剂量 (10-25 μg/kg) 下，不显著引起猕猴/恒河猴的血液学参数的变化，在高剂量 (50-175 μg/kg) 下，可升高外周血单核细胞和前单核细胞数量，呈剂量依赖性下降血小板计数，降低血浆总胆固醇和 LDL-C 水平^[1]。

The ED₅₀ is <5 ng/mL as measured by Murine M-NFS-60 cells, corresponding to a specific activity of >2 × 10⁵ units/mg.

• 
  Measured in a cell proliferation assay using M-NFS-60 mouse myelogenous leukemia lymphoblast cells. The ED₅₀ for this effect is 0.9606 ng/mL, corresponding to a specific activity is 1.041×10⁶ U/mg.

Human

CHO

Tag Free

P09603-3 (E33-S190)

1435  [NCBI]

Partial

EEVSEYCSHMIGSGHLQSLQRLIDSQMETSCQITFEFVDQEQLKDPVCYLKKAFLLVQDIMEDTMRFRDNTPNAIAIVQLQELSLRLKSCFTKDYEEHDKACVRTFYETPLQLLEKVKNVFNETKNLLDKDWNIFSKNCNNSFAECSSQGHERQSEGS

Approximately 18-22 kDa due to the glycosylation.

• 
  Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized after extensive dialysis against PBS or PBS, pH 7.4, 8% trehalose.

<0.2 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Garnick MB, et al. Preclinical and clinical evaluation of recombinant human macrophage colony-stimulating factor (rhM-CSF). Int J Cell Cloning. 1990 Jan;8 Suppl 1:356-71.  [Content Brief]

  [2]. Hamilton JA. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol. 2008 Jul;8(7):533-44.  [Content Brief]

  [3]. Rioja I, et al. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008 Aug;58(8):2257-67.  [Content Brief]